DYRK2 and hepatocellular carcinoma: This model is consistent with experimental data when DYRK2 levels are manipulated in carcinoma cell lines (ovary, CRC and HCC) that are then used as xenografts in mice, whereby DYRK2 gene silencing confers an enhanced proliferative capacity and metastatic potential in vivo [139,145,146].